Jupiter Neurosciences, Inc. (JUNS)
NASDAQ: JUNS · Real-Time Price · USD
0.5100
-0.0099 (-1.90%)
At close: Feb 23, 2026, 4:00 PM EST
0.5200
+0.0100 (1.96%)
After-hours: Feb 23, 2026, 4:00 PM EST
Jupiter Neurosciences Employees
Jupiter Neurosciences had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
4
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,899,373
Market Cap
17.56M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 4 | 0 | - |
| Jun 30, 2024 | 4 | - | - |
| Mar 31, 2024 | 4 | - | - |
| Dec 31, 2023 | 4 | -1 | -20.00% |
| Sep 30, 2022 | 5 | 0 | - |
| Jun 30, 2022 | 5 | 0 | - |
| Mar 31, 2022 | 5 | 0 | - |
| Sep 30, 2021 | 5 | - | - |
| Jun 30, 2021 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CASI Pharmaceuticals | 233 |
| Citius Pharmaceuticals | 23 |
| Serina Therapeutics | 13 |
| FibroBiologics | 13 |
| VYNE Therapeutics | 13 |
| Lexaria Bioscience | 7 |
| Pasithea Therapeutics | 4 |
| Cadrenal Therapeutics | 4 |
JUNS News
- 11 hours ago - Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution - GlobeNewsWire
- 26 days ago - Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users - GlobeNewsWire
- 27 days ago - Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference - Accesswire
- 2 months ago - Join Jupiter Neurosciences' Exclusive Live Investor Webinar and Q&A Session on January 6 - GlobeNewsWire
- 2 months ago - Jupiter Neurosciences to Participate in NobleCon21 - Newsfile Corp
- 4 months ago - Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing - GlobeNewsWire
- 6 months ago - Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador - GlobeNewsWire
- 7 months ago - Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science - GlobeNewsWire